Recall Z-0722-2007
Abbott Laboratories Inc. · initiated January 30, 2007
Product
Clinical Chemistry Phosphorus in vitro diagnostic, List Number: 7D71-30 and 7D71-20
Codes / lots: 42020HW00 & 44037HW00
Reason for recall
Patient results are falsely decreased by up to 15% at these levels: 1) Serum Plasma phosphorus greater than 8.0 mg/dL (2.60 mmol/L) 2) Urine phosphorus greater than 80.0 mg/dL (25.80 mmol/L)
FDA-determined cause: Other
Action taken
A Product Correction letter dated January 30, 2007 provided to all Clinical Chemistry Phosphorus customers that have received lot numbers 42020HW00 and 44037HW00 stating that patient results are falsely decreased by up to 15% at these levels: Serum/Plasma phosphorus greater than 8.0 mgldL (2.60 mmol/L) and Urine phosphorus greater than 80.0 mg/dl. (25.80 mmol/L). Modified linearity ranges are provided in the letter that are to be implemented when using the two lots. Instructions are also provided for changing the linearity range on the Architect cSystem as well as the Aeroset System. Customers are instructed that If they have forwarded any of Information the Clinical Chemistry Phosphorus lots listed above to another laboratory to provide a copy of this letter to them. A customer response form is provided.
Details
- Recall number
- Z-0722-2007
- Initiated
- January 30, 2007
- Posted by FDA
- April 5, 2007
- Terminated
- August 10, 2011
- Product code
- CEO – Phosphomolybdate (Colorimetric), Inorganic Phosphorus
- Quantity
- 42020HW00 - 1,351 units worldwide; 44037HW00 - 314 units worldwide
- Distribution
- Worldwide, including USA, Canada, Trinidad & Tobago, Bahamas, Panama, Cayman Islands, Jamaica
- Recalling firm
- Abbott Laboratories Inc., South Pasadena, CA